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A successful microbicide  
would be a product—likely  
delivered in a gel, foam, ring, 
or cream—that would reduce 
the transmission of HIV and, 
possibly, other sexually transmitted infec-
tions when used during intercourse. A  
number of candidate products are being  
developed,1 and several are expected to 
complete safety and efficacy trials in the 
near future. Researchers and program 
planners are considering how an effec-
tive microbicide can be made available to 
the women who need it most. Microbicide 
introduction efforts will need to be carried 
out within a range of local social contexts 
and service environments, and will have to 
consider the various cultural practices sur-
rounding marriage, sexual violence and co-
ercion, and women’s economic dependence 
on men that leave many women vulnerable 
to HIV and AIDS. 
Because microbicides are a new prod-
uct category, no clear model exists for 
how best to introduce and integrate mi-
crobicides into developing-country health 
systems. However, experience with intro-
ducing contraceptives and other health 
care technologies provides evidence and 
insights that can inform microbicide intro-
duction. Drawing on its leadership in the 
microbicide field and its long history of 
work in product development and intro-
duction, the Population Council convened 
a day-long meeting of experts to review 
product introduction experiences and iden-
tify key features that can guide microbicide 
introduction. This Day of Dialogue brought 
together 45 leaders from two dozen non-
governmental, governmental, advocacy, 
and donor organizations. Speakers and 
participants have backgrounds in product 
introduction and social marketing, clinical 
trials and product development, and re-
productive health and HIV/AIDS and have 
extensive experience in designing and 
implementing introduction programs in 
developing countries.2
The meeting was designed to highlight 
lessons from a range of technology intro-
1 For an overview of microbicide product development see www.microbicide.org.
2 A listing of presentations and participants appears on pages 11–16 of this report.
Presentation topics included 
• Building a platform for women’s  
HIV prevention
• Update on the microbicides pipeline
• Emergency contraception: Use dynamics 
and messaging
• Challenges and opportunities related to  
the female condom
• Introducing a package of products: 
Cyclebeads, condoms, and EC
• Commercialization of products for “taboo” 
health areas: An industry perspective
• Social marketing of health products that 
require new behavior: A look at bednets 
and point-of-use water treatment
• A process of innovation: History of  
contraceptive implants (Norplant®)
• Emerging tools in HIV prevention:  
Male circumcision
• Lessons for microbicides: Facilitated  
discussion
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duction experiences: emergency contra-
ception, the female condom, the standard 
days method (SDM) of fertility awareness,3 
insecticide-treated bednets, point-of-use 
water treatment, and Norplant®. These 
are examples of prevention products (to 
prevent either pregnancy or disease) that 
require information and support to be used 
effectively and have varying levels of ef-
fectiveness. Because first-generation candi-
date microbicides are also user-controlled, 
involve sex and sexual practices, and chal-
lenge gender norms, lessons from existing 
products that share similar features—in-
cluding emergency contraception and the 
female condom—are relevant. Other speak-
ers reviewed private-sector approaches to 
introducing “taboo” health products, and 
the status of male circumcision for prevent-
ing HIV infection.
This report outlines some of the key 
lessons and findings that emerged under 
several broad themes: increasing HIV pro-
tection; putting effectiveness into perspec-
tive; disentangling need, demand, and use; 
bridging clinical trials and health system 
integration; considering population-level 
versus individual-level risk and benefits; 
and product positioning and marketing 
strategies. All of these have implications for 
clients, providers, health delivery systems, 
and policy decisionmaking. While these 
cases and practical experiences should in-
form microbicide introduction, this critically 
important effort will need to combine both 
science—derived from evidence and expe-
rience—and art—drawing on creative and 
innovative thinking.
Increasing HIV protection  
by expanding options 
Microbicides need to be  
introduced as part of a broad 
public health goal of increas-
ing overall levels of protection 
and offering women more  
options for protection.
This will necessitate exploring how people 
make tradeoffs among different methods 
based on availability, perceived effective-
ness, price, ease of use, and other factors. 
Lessons related to contraceptive use sug-
gest that offering more options makes it 
more likely that women and couples can 
adopt a method that fits their needs. When 
considering introducing the standard days 
method (SDM), policymakers and provid-
ers were concerned that women would 
“switch” from other methods of contracep-
tion to the less effective SDM. However, 
research suggests that SDM attracted new 
contraceptive users, many of whom ob-
jected to other methods of contraception 
for different reasons: side effects, finding 
them difficult to use, perceived as be-
ing “unnatural,” or on religious grounds. 
Similarly, incorporating female condoms 
into the method mix can increase the num-
ber of sex acts protected by both male and 
female condoms.
One approach to preparing for microbi-
cide introduction is to build a “platform” 
for girls’ and women’s protection strategies 
by situating the introduction of women’s 
3 The Standard Days Method (SDM) is a family planning method that standardizes fertility awareness. It is used with 
cyclebeads, which are a color- coded string of beads that help a woman track her cycle days, know when she is fertile, 
and monitor her cycle length. The SDM identifies days 8–19 of the cycle as fertile, and helps couples avoid unplanned 
pregnancy by knowing on which days they should not have unprotected sex, and can also help couples plan pregnancy 
by knowing on which days the woman is fertile.
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HIV prevention products within a broader 
protection framework. Such an approach 
would focus on issues of equity and access 
to HIV prevention products and services; 
would include actions to redress gender-
related power imbalances within societies, 
households, and intimate partnerships; 
and would make a concerted effort to 
enhance women’s economic opportuni-
ties. This approach also requires breaking 
through the bottlenecks that have ham-
pered the introduction of female-initiated 
products by investing in training, commu-
nication, and outreach, and by expanding 
the concept of service delivery to include 
a new set of actors, mechanisms, settings, 
and types of providers.
Experience with a range of health prod-
ucts has demonstrated the feasibility and 
acceptability of providing them outside 
clinic settings with little negative impact on 
quality. Research comparing clinic and com-
munity-based provision of SDM found no 
meaningful difference between the compe-
tency of these different provider types. This 
finding demonstrates that even a technology 
with extensive counseling and information 
requirements can be provided appropri-
ately outside a formal clinic setting. At the 
same time, emergency contraception has 
increasingly been made available without a 
prescription; while this improves access it 
can compromise the quality of information 
and women’s understanding of the product, 
unless efforts are made to ensure adequate 
provision of information. Such approaches 
are important to increase access to new 
prevention technologies in settings that are 
comfortable and convenient for different us-
ers. Striking a balance between relying on 
a wide range of distribution channels and 
maintaining the ability to monitor and eval-
uate patterns and dynamics of use is essen-
tial, particularly in early stages of product in-
troduction. It is also essential to strengthen 
and retool existing HIV prevention programs 
to lay the foundation for microbicides and 
other new prevention technologies.  
Putting effectiveness into  
perspective 
The microbicide field will  
continue to grapple with  
issues surrounding product  
efficacy and use effectiveness
as it considers product introduction. Policy-
makers, providers, and activists sometimes 
express concerns about introducing a par-
tially effective product like a microbicide for 
HIV prevention. How efficacious a microbi-
cide must be, however, is shaped by the al-
Female-initiated, coitally dependent 
methods require
Addressing provider bias up front
A long-term perspective and commitment: 
• acceptability changes over time 
• individual users have a learning curve and 
become more comfortable with the product 
over time 
Incorporating concepts of sex, sexuality, and 
communication and negotiation skills into 
counseling and information provision
Challenging assumptions about sex and  
sexuality
Realistic expectations: “consistent” use is 
optimal but difficult to achieve
Sustained political and financial support to 
programs
4
ternatives. In the contraceptive field a 40–60 
percent efficacious product would likely not 
be viable when compared with other con-
traceptive products with much higher ef-
ficacy—sometimes greater than 90 percent. 
But HIV prevention is very different. There 
are few effective options, and those that do 
exist—male and female condoms—are not 
widely available or used. In this context a 
partially effective product that is used con-
sistently could offer an important protection 
strategy at both the population and indi-
vidual levels.
People may be willing to tolerate differ-
ent levels of imperfection (in a technology 
and in use of the technology) depending on 
their assessment of their own risk factors 
and the benefit the product may confer. For 
example, women and couples using SDM 
perceived it as a very effective contracep-
tive method because they were compar-
ing it to the method they were currently 
using—nothing—rather than to highly 
efficacious methods like the IUD or pill 
that they were unable or unwilling to use. 
Microbicides will need to be introduced in 
the context of the range of prevention op-
tions such as male and female condoms, 
and women will need to understand the dif-
ferent levels of protection that each option 
affords. While it is unclear how individuals 
will balance considerations of effective-
ness, ease of use, price, convenience, and 
pleasure, it is critical to ensure that women 
are provided with accurate and meaningful 
information about a product’s effectiveness 
so that they can make their own assess-
ments of different prevention options. The 
microbicide field could begin to develop 
and test communication and counseling 
strategies, information materials, provider 
training curricula, and policy initiatives to 
address the concepts and messages sur-
rounding partial efficacy.
Disentangling need, demand, 
and use
The relationships between 
need, demand, and use of 
new products are complex 
and non-linear. Epidemiological data 
underscore the devastating impact of the 
AIDS epidemic and new HIV infections on 
women, who have few options under their 
control for preventing infection. Market 
research and acceptability studies show 
that women in various settings and circum-
stances express a high level of interest in 
microbicides. It is not clear, however, how 
these high levels of need and interest will 
translate into demand for a particular prod-
uct once it is available. This uncertainty is 
even more pronounced for a product like a 
microbicide that is a “public health good” 
for which demand will need to be created, 
measured, and sustained among providers, 
policymakers, donors, and users. Provider 
and policymaker bias against the female 
condom interacted with the product’s limi-
tations, relatively high price, and need to 
provide information and support, with the 
result that widespread availability and use 
were curtailed. 
Because microbicides are a new product 
category, demand for them will have to 
be created. Social marketing can play an 
important role in creating demand for mi-
crobicides by using mass media and other 
marketing approaches to increase under-
standing of disease transmission and how 
microbicides work, and to instill a belief 
in the benefits of the product. Such efforts 
have been used successfully for a variety 
of other products, including insecticide-
treated bednets to prevent malaria and 
point-of-use water treatment to prevent 
diarrheal disease.
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Acceptance and use of the “first-to- 
market” microbicide will set the stage—in 
both positive and negative ways—for fu-
ture products. Therefore it is critical that 
initial introduction efforts are well con-
ceived, well supported, and successful. 
Experience from other products suggests 
that it takes time to establish both a market 
and a reliable system to deliver the prod-
uct—as illustrated by virtually all of the 
examples explored at the Day of Dialogue. 
Even with a product that is urgently need-
ed, adoption is likely to be  characterized 
by fits and starts. Donors and other key 
opinion leaders must be realistic about 
the time trajectory needed for widespread 
product adoption. 
Population and individual  
impact 
Public health advocates  
have long relied on modeling 
to estimate the population-
level impact of new preven-
tion technologies in order to build 
the case for investing in development and 
delivery of these products. As evidenced 
by several examples, however, it can be 
very difficult to demonstrate this kind of 
population-level impact, especially in the 
near term. Attempting to do so can create 
unrealistic expectations about the tim-
ing and rate of introduction, acceptance, 
and use of new prevention technologies. 
Demonstrating population-level impact in 
the early years of product adoption is not 
likely to be feasible for several reasons. 
First, almost all new products require time 
and substantial investment in order to be 
made widely available and used consis-
tently. Second, measuring the public health 
impact of a new technology can be dif-
ficult—it requires a large amount of data 
collected over a long period of time, and it 
can be very difficult to tease out the impact 
of the technology itself from other interven-
tions or broader societal changes. Typically, 
population-level impact of a prevention 
strategy is only visible after a long period—
often decades.
Measuring impact has been a challenge 
for many products. For example, both in-
secticide-treated bednets and point-of-use 
water treatment have achieved increased 
sales in a number of settings where con-
certed investment has been made in so-
cial marketing programs. While a number 
of studies have shown that use of these 
products has increased along with sales, 
it has been difficult to measure impact on 
decreases in malaria or diarrheal disease. 
In seeking to expand access to emer-
gency contraception (EC), a number of 
public health researchers and advocates 
maintained that doing so would lead to a 
decrease in unintended pregnancy and in-
duced abortion, and they developed models 
to estimate the likely impact in different set-
tings. While information about, access to, 
and use of EC have increased dramatically, 
recent research has been unable to dem-
onstrate that EC has had a population-level 
impact on rates of unintended pregnancies 
and/or induced abortion. 
The microbicide field should learn from 
these experiences. Researchers, public 
health officials, and advocates should be 
careful about basing an argument for prod-
uct introduction solely on the expectation 
of a measurable impact on reducing HIV 
infection in women within a short time-
frame. While having an impact on the AIDS 
epidemic is clearly the intention of those 
working on microbicides, making the case 
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for microbicide introduction should also be 
based on the human rights goal of provid-
ing more options for individuals—espe-
cially women—to reduce their risk of infec-
tion. This approach, coupled with careful 
monitoring and research, can help make 
the case for microbicides—and other new 
HIV prevention options—based on their 
benefits for both individuals and the popu-
lation overall. 
Bridging clinical trials and  
health system integration:  
Pre-introduction studies 
After completing clinical  
trials, and during the time 
that regulatory files are being 
prepared and reviewed,
researchers and service providers can 
continue to explore operational questions 
concerning product delivery that will not be 
addressed in a clinical trial. For example, 
social science and operations research can 
explore the feasibility and acceptability 
of various approaches to service delivery, 
training, and supervision for different types 
of providers. Research can also explore 
issues related to logistics and supply sys-
tems, patterns of use, and provision of in-
formation to users. 
The experience with Norplant® implants 
provides an example of this pre-introduc-
tion phase as a bridge between clinical tri-
als and widespread introduction through 
incorporation into national programs. The 
pre-introduction phase was pioneered by 
the Population Council in the 1980s to move 
products from clinical trials into national 
programs while ensuring attention to qual-
ity of care. This approach provides an op-
portunity to carefully and systematically 
introduce a product under more routine ser-
vice conditions while continuing to closely 
monitor, control, and study the process. As 
described above, data and experience are 
generated on aspects of the product that 
are not studied in clinical trials, such as 
operational issues about product delivery, 
integration into health systems, and longer-
term behavioral dimensions of product use. 
Examples from Norplant and emergency 
contraception presented at the meeting un-
derscored the importance of carefully plan-
ning the scope and setting for pre-introduc-
tion studies. In each case, an international 
consortium worked on various aspects of 
Benefits of a pre-introduction phase 
A pre-introduction phase offers an opportuni-
ty to address issues that can inform and im-
prove product introduction. A well-designed 
and monitored pre-introduction phase: 
• Serves as a bridge between the clinical 
trial and widespread incorporation into 
national programs
• Allows providers and health systems to 
gain experience with the product under 
routine service conditions
• Provides critical training to medical opin-
ion leaders
• Allows for monitoring and gathering data 
on practical aspects of service delivery 
that are not routinely collected in trials
• Builds partnerships between technical 
agencies with unique capacities (e.g.  
service delivery; information, education, 
and communication; monitoring  
and evaluation) 
• Offers opportunities for expanded com-
munity engagement and policy dialogue 
to establish a good foundation for product 
introduction
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product availability and delivery, including 
planning the pre-introduction and other 
operations research efforts. Both consortia 
used a consultative process to determine 
the key questions to be addressed in these 
studies, and to develop the appropriate 
protocols to examine those questions. 
The Emergency Contraception Consortium 
developed different approaches that were 
tested in four countries. Pre-introduction 
studies for both Norplant and EC were con-
ducted in settings where the products were 
new, as well as in settings where trials had 
been conducted. (In contrast to the case of 
microbicides, EC and Norplant trials were 
conducted and initial regulatory approv-
als were granted in developed countries.) 
Lessons from EC and Norplant underscore 
the importance of selecting countries and 
settings for pre-introduction studies that 
are open to innovation and where there is a 
reasonable likelihood for success.  
Marketing approaches:  
Insights from private-sector  
and social marketing 
A number of lessons from  
private-sector and social  
marketing were presented at 
the meeting to inform micro-
bicide introduction strategies.
In the private sector, marketing is a key 
consideration in the early stage of product 
development; in many cases marketing is 
a driving force behind product develop-
ment through defining product features. 
Microbicide development has been influ-
enced by social science and behavioral 
research among diverse groups of potential 
users to explore key product attributes and 
use dynamics. While some of these find-
ings have been incorporated into product 
development, technical considerations 
have limited the extent to which this has 
been possible in first-generation gel-based 
products. More recent developments in the 
microbicide field—for example, progress 
on a vaginal ring and longer-acting topical 
formulations—are in part responding to ex-
pressed user preferences. The field should 
continue to conduct market and acceptabil-
ity research among diverse groups and use 
findings to inform product development 
Product introduction frameworks
Many product introduction efforts have devel-
oped frameworks that outline critical elements 
of the process. These frameworks use different 
terminologies and generally reflect the unique 
characteristics of the product being consid-
ered, be it emergency contraception, Norplant, 
or the female condom. Nevertheless, most of 
them share a number of common elements:
• Assess users’ needs and perspectives
• Create a communication strategy
• Determine service capacity and ability to 
deliver
• Build policy, financial, and provider  
support
• Obtain registration and regulatory approval
• Ensure supply of product through financing 
and procurement mechanisms
• Develop distribution plans
• Conduct provider training
• Conduct ongoing monitoring and evaluation
• Develop, implement, and adapt programs 
for user education and support
The microbicide field can build on and adapt 
these elements to develop a microbicide-spe-
cific introduction strategy. 
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and to guide investment decisions that will 
determine which products should advance 
through the pipeline.  
As the field moves from product develop-
ment to product introduction and use, other 
lessons from marketing will apply. Patterns of 
use of new technologies can be generalized 
based on theories of diffusion and innovation. 
Typically, a number of factors influence  
the rate at which a new product is adopted: 
how much behavior change is required, 
product cost, and investment in marketing.
A number of other key considerations 
from the marketing field are applicable to 
microbicide introduction: 
• Defining market size and market poten-
tial: Various approaches and modeling 
exercises are used to estimate market 
size for health care products. When as-
sessing potential markets, forecasters 
examine past and present practices of 
current users of similar products, iden-
tify the key determinants of product use, 
and determine what predictions can be 
made about the future. Because micro-
bicides are a new product category, such 
analyses are more complicated. 
• Market segment prioritization: 
Prioritization of different market seg-
ments is key for growth of a specific 
product as well as for the overall product 
category. Prioritization allows for clearer 
focus on specific user groups, leading to 
more effective communication strategies. 
There is a great deal of diversity even 
within “market segments,” which needs 
to be considered in product positioning 
and service delivery approaches. For 
example, an effort to reach “young wom-
en” would need to address the heteroge-
neity of this potential user group: some 
young women live beyond protective 
structures of family and school; some are 
under pressure to exchange sex for gifts, 
money, or shelter; many are married, 
while others are unmarried but sexually 
active. To reach this diverse group will re-
quire careful product positioning, as well 
as identifying and/or creating new social 
and health delivery platforms.
• Product positioning: Typically, a product 
is positioned on the basis of one key 
characteristic, generally its primary ben-
efit. Microbicides could be positioned 
in terms of disease prevention, promot-
ing sexual health, or enhancing sexual 
pleasure. Determining how to position a 
microbicide will depend on the product 
profile, including its regulatory status, 
and on the primary market or user group 
being targeted. For example, a product 
might be positioned differently for mar-
ried women than for unmarried adoles-
cents. Decisions on product positioning 
are critical for the first product of its kind 
to come to market and in determining 
the possibilities for positioning any sub-
sequent products. 
• Product life cycle planning: It is impor-
tant to plan the product pipeline. Efforts 
to introduce a new product need to an-
ticipate what effect the first generation 
will have on subsequent products in the 
same category. There are clear advantag-
es and disadvantages of a product being 
first to market. The first product can capi-
talize on being new and innovative, and 
can potentially build a loyal base among 
initial users. It can also pave the way by 
introducing and popularizing a concept 
and by addressing difficult issues. For 
example, as Norplant was being intro-
duced, a second-generation product was 
already coming on line; some countries 
opted to wait for this second-generation 
product, which was expected to be less 
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expensive and easier to deliver. Major 
considerations for planning and antici-
pating the impact of later-generation 
products are how quickly they are likely 
to reach the market and the extent to 
which users will substitute a new prod-
uct for the current one.
• Market development and market seeding: 
Market development involves preparing 
the market to accept a new product. Some 
approaches include increasing health-
seeking behavior and legitimizing the 
health condition that a new product will 
address. For example, a number of phar-
maceutical companies have done exten-
sive direct-to-consumer marketing to de-
stigmatize depression in order to increase 
sales of anti-depressants. Market seeding 
or pre-launch activities include conducting 
observational studies, educating health 
care professionals, forming partnerships 
with advocacy organizations, and con-
ducting public awareness campaigns. 
In the microbicides field a number of the 
aforementioned activities are underway, 
and others are being planned. It would 
be useful to review and consolidate some 
of these efforts and to identify key areas 
where additional work would be productive. 
In some cases, it may be more appropriate 
to reconceptualize “advocacy” activities as 
“market development” and to consider allo-
cating funds for these efforts as an essential 
product development cost. 
Additional research and  
next steps
A number of potential next steps and prior-
ity actions can be initiated now, including: 
• Establish an interagency microbicides 
introduction working group to plan, coor-
dinate, and implement relevant activities. 
• Develop a prototype pre-introduction pro-
tocol for adaptation to different settings. 
• Convene a follow-on consultation on cur-
rent HIV prevention programs and impli-
cations for microbicide introduction.
• Develop a protocol for the design, 
implementation, and evaluation of an 
“expanded choice” intervention, which 
would include male and female con-
doms and microbicides.
• Convene advertising/marketing experts 
to brainstorm marketing strategies for 
the microbicide product category.
• Identify feasible and acceptable access 
strategies for adolescent girls in key 
countries.  
• Consolidate and expand key “market 
seeding” (pre-launch) activities such as:
– Initiatives to stimulate health-seeking 
behavior, particularly among adoles-
cents
– Educational events, technology up-
dates, and outreach to health care  
professionals 
– Development of “champions” in key 
countries 
• Plan and initiate research on key issues 
for microbicides and other new preven-
tion technologies—for example: 
– What evidence is needed in key coun-
tries to inform national decisions regard-
ing adoption of microbicides and how 
they fit into national programs, health 
systems, and the overall mix of HIV pre-
vention technologies and programs?
– How do women and girls assess their 
risk of HIV? How does this self-as-
sessment correspond to actual risk? 
What practical strategies do women 
and girls adopt to protect themselves? 
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What are the implications of these re-
lationships for microbicides? 
– How can diverse populations of ado-
lescent girls be effectively and reli-
ably reached with information and 
products? What kinds of social and/or 
health delivery platforms currently 
exist, and how can they be prepared 
to adequately deliver microbicides  
and other HIV-prevention products?  
Where none exist, what is the best 
way to establish them? 
– How can issues of efficacy and a hi-
erarchy of different methods best be 
explained to potential users? What 
information, counseling, and support 
strategies will be needed to ensure 
safe and effective use?
– What combination of service delivery 
approaches and mechanisms will be 
most appropriate for an initial micro-
bicide product? What targeted areas 
for health systems strengthening are 
needed?
– What would a “prevention package” 
look like in terms of products, mes-
sages, and delivery, and how could 
introduction efforts be designed to 
embrace the concept of an expanded 
choice hierarchy? 
As research on microbicides advances, it 
is important to continue to draw on experi-
ence from other products when consider-
ing how best to make proven microbicides 
available to women. Participants from 
many sectors—such as the pharmaceutical 
industry, advocacy groups, policymakers, 
and public health officials—will bring differ-
ent perspectives and objectives to this en-
deavor. The collective insights, experience, 
and commitment of these groups will be 
required to meet the challenge of providing 
women with the tools to protect themselves. 
Suggested websites for further information
Alliance for Microbicide Development (AMD) www.microbicide.org
Contraceptive Research and Development Program (CONRAD) www.conrad.org
Family Health International (FHI) www.fhi.org/en/index.htm
Global Campaign for Microbicides www.global-campaign.org
HIV Prevention Trials Network (HPTN) www.hptn.org
International Partnership for Microbicides (IPM) www.ipm-microbicides.org
Microbicides Development Programme (MDP) www.mdp.mrc.ac.uk
Microbicide Trials Network (MTN) www.mtnstophiv.org
National Institutes of Health (NIH) www.nih.gov
Population Council www.popcouncil.org
US Agency for International Development (USAID)  www.usaid.gov
World Health Organization www.who.int/en
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Day of Dialogue
Insights and Evidence from Product Introduction: Lessons for Microbicides
12 March 2007
Population Council, New York
PRESENTATIONS
9:00 - 9:20 Welcome
Peter Donaldson, Population Council
9:20 - 9:45 
 
Building the Platform for Women’s HIV Prevention
Martha Brady, Population Council 
This session will introduce the agenda and objectives for the day. The speaker 
will then provide an overview of girls’ and women’s protection strategies, how 
microbicides fit within an overall approach to HIV risk management, and key 
issues for microbicide introduction.
9:45 - 10:05 
 
Update on the Microbicides Pipeline
An overview of the microbicide product development pipeline highlighting the 
different mechanisms of action being explored, as well as the stage of development 
and general characteristics of products in clinical trials.
Speaker: Polly Harrison, Alliance for Microbicide Development
Facilitator: Lee Claypool, USAID
10:05 - 10:45 Emergency Contraception: Use Dynamics and Messaging
This session will address the issues associated with a user-dependent, coitally 
related product where use is strongly correlated with quality of information. The 
presentation will include a discussion of how the message, messenger, provider, 
and service type influence use. The speaker will highlight the challenges of 
taking a product over the counter, re-supply, and scaling up, and the strategic 
considerations and implications of advance provision versus post-exposure. 
Speaker: Elizabeth Westley, International Consortium on EC
Facilitator: Ian Askew, Population Council
10:45 - 11:00 Break 
11:00 - 11:40 Challenges and Opportunities of the Female Condom 
This session will review lessons from the female condom: the only female-
initiated HIV prevention product currently available. The speaker will describe 
public-sector and social marketing approaches, highlighting different strategies 
to positioning and providing the female condom (FC). He will describe how the 
FC delivery platform may be useful for microbicides. 
 Speaker:  Mitchell Warren, AIDS Vaccine Advocacy Coalition
Facilitator: Naomi Rutenberg, Population Council
11:40 - 12:20 Introducing a Package of Products: CycleBeads, Condoms, and EC
The speaker will discuss the rationale, development, and evolution of a 
“package of interventions” to achieve a single reproductive health goal. 
The presentation will examine how complex messages are communicated, 
approaches to counseling, and how this package moved from clinical study to 
public health programs and use.
Speaker:  Victoria Jennings, Georgetown University 
Facilitator: Elizabeth McGrory, Consultant 
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12:20 - 1:00 Break
1:00-1:45 Lunch Speaker
Commercialization of Products for “Taboo” Health Areas: An Industry Perspective
Barbara Feringa, Marketing Consultant
This session will briefly explore the strategies used by the private sector in 
marketing products that address “taboo” health issues. Topics to be discussed 
include identifying market size and market potential, market segmentation, 
product positioning, life cycle management, and product adoption. The 
incorporation of market development strategies to achieve sustainable 
growth will be discussed, as will its implications for product launches and line 
extensions.
 Facilitator: Martha Brady, Population Council
1:45-2:25 Social Marketing of Health Products that Require New Behavior: A Look at Bednets 
and Point-of-Use Water Treatment
The presentation will examine how social marketing approaches are used 
to initiate new behaviors for disease prevention. The speaker will describe 
the experience with bednets for malaria prevention, and point-of-use water 
treatment for prevention of diarrheal disease. 
Speaker:  Brad Lucas, Population Services International 
Facilitator: Saul Walker, International Partnership for Microbicides
2:25–3:05 A Process of Innovation: History of Contraceptive Implants (Norplant®)
This session will review the process of introducing a first-generation, new 
contraceptive product within the context of the family planning paradigm. The 
speaker will highlight the “pre-introduction” phase developed to bridge clinical 
trials and introduction, and how Norplant served as a catalyst for quality of care 
and the strategic approach to contraception introduction. He will also highlight 
some of the political minefields the effort faced, and the challenges of being first 
to market. 
Speaker:  Juan Díaz, Population Council 
Facilitator: Sarah Harbison, USAID
3:05 – 3:15 Break
3:15-3:45 Emerging Tools in HIV Prevention: Male Circumcision
This session will review the newest approach to HIV prevention through recent 
clinical trial results, and discuss how the HIV-prevention field is approaching 
translating these findings from research to practice. The speaker will touch 
on the implications for population-level risk reduction versus individual risk 
reduction, behavioral disinhibition, and how these issues are being considered 
at the policy, program, and user levels.
Speaker:  Johannes van Dam, Population Council
Facilitator:  Kim Dickson, World Health Organization
3:45-4:45 Lessons for Microbicides: Facilitated Discussion 
Participants and speakers will be invited to draw on the presentations and 
discussion to review and identify lessons for microbicides.
 Discussant: Jeff Spieler, USAID
Chair:  Lori Heise, Global Campaign for Microbicides
4:45 Closing Remarks
Martha Brady, Population Council
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